The efficacy and safety of collagenase clostridium histolyticum ( CCH ) in patients with Dupuytren 's contracture ( DC ) was demonstrated in a program including two pivotal phase 3 clinical trials ( CORD I and II ) which included patients with a broad range of disease severity .